Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

Life Molecular Imaging Applauds the Publication of the IDEAS Study Aim I Results

8. Apr 20198. Apr 2019lifemolecular

Read more: Publication of IDEAS study aim 1 results shows that Amyloid PET Imaging was associated with changes in clinical management for Medicare beneficiaries with MCI, dementia, cognitive impairment or Alzheimer’s Disease

Related

Post navigation

← Life Molecular Imaging Announces Presentation of New Clinical Data of the Next Generation Tau PET Tracer PI-2620 at the AD/PD 2019 Conference
Life Molecular Imaging and Institut de Radiofarmàcia Aplicada de Barcelona (IRAB) Announce a Strategic Partnership for Production of NeuraCeq and PI-2620 in Barcelona →
© Copyright 2018 Life Molecular Imaging
Imprint / Data protection
Contact
Scroll to Top
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection